Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. SanBio Company Limited
  6. News
  7. Press Releases
    4592   JP3336750009

SANBIO COMPANY LIMITED

(4592)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société SANBIO COMPANY LIMITED
10/18SANBIO : Notice on Appointment of New Corporate Officer
PU
10/14SANBIO : Announcement on Granting Stock Options (Share Acquisition Rights)
PU
09/21SANBIO : Notice on Recording of Non-Operating Income and Extraordinary Loss
PU
09/16SANBIO : Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending ..
PU
09/14SANBIO : Consolidated Financial Results for the Six Months Ended July 31, 2021
PU
09/14SANBIO : Notice Concerning Difference Between Consolidated Financial Forecasts and Actual ..
PU
08/31SANBIO : Notice on Conclusion of Committed Credit Line Agreement with MUFG Bank, Ltd
PU
07/29SANBIO : Determination of Terms and Conditions of Stock Options
PU
07/14SANBIO : Announcement on Granting Stock Options (Share Acquisition Rights)
PU
07/01SANBIO : Notice Concerning Changes to Our Lineup of Corporate Officers
PU
06/23SANBIO : Announcement on Acquisition and Cancellation of Stock Options (Share Acquisition ..
PU
05/14SANBIO : Determination of Terms and Conditions of Stock Options
PU
04/28SANBIO : Announcement on Granting Stock Options (Share Acquisition Rights)
PU
04/14SANBIO : Notice Regarding Change of Representative Director
PU
03/18SANBIO : Presentation for Financial Results for the Fiscal Year Ending Jan.31, 2021
PU
03/17SANBIO : Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and A..
PU
03/17SANBIO : Consolidated Financial Results for the Fiscal Year Ended January 31, 2021
PU
02/28SANBIO : Presentation of STEMTRA Phase 2 Trial Results at the 44th Annual Meeting of the J..
PU
02/26SANBIO : Notice Concerning Extraordinary Gains (Gain on Sales of Investment Securities) an..
PU
02/25SANBIO : Revision of Consolidated Earnings Forecast for the Fiscal Year Ended January 2021
PU
02/25SANBIO : Announcement on Granting Stock Options (Share Acquisition Rights)
PU
01/04SANBIO : Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology
BU
2020SANBIO : Consolidated Financial Resultsfor the SixMonthsEnded July 31, 2020
PU
2020SANBIO : Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending ..
PU
2020SANBIO : Notice regarding change in director and corporate officer
PU
2020SANBIO : Additional analytical results of the US-based Phase 2b clinical trial of SB623 fo..
PU
2020SANBIO : Notice regarding the recording of non-operating expenses (foreign exchange losses..
PU
2020SANBIO : Additional Analytical Results of the US-Based Phase 2b Clinical Trial of Regenera..
BU
2020SANBIO : Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)
PU
2020SANBIO : Announcement on Granting Stock Options (Share Acquisition Rights)
PU
2020SANBIO : Notice Regarding Business Alliance Between Sanbio and Ocumension in the Research,..
BU
2019SANBIO : Granted Regenerative Medicine Advanced Therapy Designation from the U.S. FDA for ..
BU
2019SANBIO : Bijan Nejadnik, M.D., Appointed as Chief Medical Officer of SanBio
BU
2019SANBIO : SB623, an Investigational Product, Granted Advanced Therapy Medicinal Product Cla..
BU
2019SANBIO : Announces SB623 Regenerative Cell Therapy for Traumatic Brain Injury Has Received..
BU
2019SANBIO : to Announce the Results of a Phase 2 STEMTRA Trial Regarding the Use of Regenerat..
BU
2019SANBIO : Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine
BU
2018SANBIO : Announces Phase 2 STEMTRA Trial Using SB623 Cells for Treatment of Patients with ..
BU
2018SANBIO : Notice of Personnel Changes to Corporate Officers at SanBio Co., Ltd. and at US S..
BU
2018SANBIO : Supplementary Information to the Notice Regarding an Equity and Business Alliance..
BU
2018SANBIO : Notice Regarding an Equity and Business Alliance Between Five Companies for Joint..
BU
2018SANBIO : Acquisition of a Patent Portfolio Regarding Cell Medicines Derived from Mesenchym..
BU
2018SANBIO : Joint Research Agreement for SB623 Targeting Dementia
BU
2018SANBIO : Summary of Procurement of Funds in the Current Fiscal Year
BU
2018SANBIO : US-based Phase 1/2a Clinical Trial of SB623 for the Treatment of Chronic Motor De..
BU
2018SANBIO : Research Paper Co-authored by Dr. Damien Bates, Chief Medical Officer and Head of..
BU
2018SANBIO : Update on Development Progress of Regenerative Cell Medicine SB623
BU
2018SANBIO : Primary Researcher Receives 2017 Smithsonian American Ingenuity Award
BU
2017SANBIO : Names Mohammad El-Kalay New Technical Operations SVP
BU
2017SANBIO : Study of SanBio's Stem Cell Treatment for Stroke Receives Innovation Award from A..
BU
Upcoming event on SANBIO COMPANY LIMITED
12/15/21